rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2017-474-484rsp-2428Research ArticleМЕЖДУНАРОДНЫЕ И РОССИЙСКИЕ РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙINTERNATIONAL AND RUSSIAN GUIDELINES FOR THE TREATMENT OF RHEUMATIC DISEASESПрименение нестероидных противовоспалительных препаратов и генно-инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России»USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND BIOLOGICAL AGENTS FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIDES. RECOMMENDATIONS OF THE SPONDYLOARTHRITIS STUDY GROUP OF EXPERTS, ALL-RUSSIAN PUBLIC ORGANIZATION «THE ASSOCIATION OF RHEUMATOLOGY OF RUSSIA»ГайдуковаИ. З.GaidukovaI. Z.

410012 Саратов, ул. Большая Садовая, 112

112, Bolshaya Sadovaya St., Saratov 410012

РебровА. П.RebrovA. P.

410012 Саратов, ул. Большая Садовая, 112

112, Bolshaya Sadovaya St., Saratov 410012

ЛапшинаС. А.LapshinaS. A.

420012 Казань, ул. Бутлерова, 49

49, Butlerov St., Kazan 420012

ОттеваЭ. Н.OttevaE. N.

680009 Хабаровск, ул. Краснодарская, 9

9, Krasnodarskaya St., Khabarovsk 680009

ДубининаТ. В.DubininaT. V.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

БадокинВ. В.BadokinV. V.

125993 Москва, ул. Баррикадная, 2/1

2/1, Barrikadnaya St., Moscow 125993

БочковаА. Г.BochkovaA. G.

140300 Московская обл., Егорьевск, ул. Рязанская, 50

50, Ryazanskaya St., Egoryevsk, Moscow Region 140300

БугроваО. В.BugrovaO. V.

460000 Оренбург, ул. Советская, 6

6, Sovetskaya St., Orenburg 460000

ГодзенкоА. А.GodzenkoA. A.

125993 Москва, ул. Баррикадная, 2/1

34A, Kashirskoe Shosse, Moscow 115522

ДубиковА. И.DubikovA. I.

690105 Владивосток, ул. Русская, 76

76, Russkaya St., Vladivostok 690105

ИвановаО. Н.IvanovaO. N.

394066 Воронеж, Московский проспект, 151

151, Moskovsky Prospect, Voronezh 394066

КоротаеваТ. В.KorotaevaT. V.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

НесмеяноваО. Б.NesmeyanovaO. B.

454092 Челябинск, ул. Воровского, 70

70, Vorovsky St., Chelyabinsk 454092

НикишинаИ. П.NikishinaI. P.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522;

РаскинаТ. А.RaskinaT. A.

650029 Кемерово, ул. Ворошилова, 22а

22a, Voroshilov St., Kemerovo 650029

РумянцеваО. А.RumyantsevaO. A.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

СмирновА. В.SmirnovA. V.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

СиталоА. В.SitaloA. V.

107078 Москва, ул Новая Басманная, 9/2-4, стр. 6

9/2-4, Novaya Basmannaya St., Build. 6, Moscow 107078

ЭрдесШ. Ф.ErdesSh. F.

115522 Москва, Каширское шоссе, 34А

V.A. Nasonova Research Institute of Rheumatology

ФГБОУ ВО «Саратовский государственный медицинский университет имени В.И. Разумовского» Минздрава РоссииРоссияV.I. Razumovsky Saratov State Medical University, Ministry of Health of RussiaRussian FederationФГБОУ ВО «Казанский государственный медицинский университет» Минздрава РоссииРоссияKazan State Medical University, Ministry of Health of RussiaRussian FederationКГБОУ ДПО «Институт повышения квалификации специалистов здравоохранения» Минздрава Хабаровского краяРоссияInstitute for Postgraduate Training of Health Professionals, Ministry of Health of the KhabarovskRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian FederationМедицинский центр «Агат»РоссияAgat Medical Center, EgoryevskRussian FederationФГБОУ ВО «Оренбургский государственный медицинский университет» Минздрава РоссииРоссияOrenburg State Medical University, Ministry of Health of RussiaRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationМедицинский центр «САНАС»РоссияSANAS Medical CenterRussian FederationБУЗ ВО «Воронежская областная клиническая больница №1»РоссияVoronezh Regional Clinical Hospital OneRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationГБУЗ «Челябинская областная клиническая больница»РоссияChelyabinsk Regional Clinical HospitalRussian FederationФГБОУ ВО «Кемеровская государственная медицинская академия»РоссияKemerovo State Medical AcademyRussian FederationМРОБОИ «Общество взаимопомощи при болезни Бехтерева»РоссияMutual Aid Society of Bechterew's DiseaseRussian Federation201727102017555474484Copyright © Гайдукова И.З., Ребров А.П., Лапшина С.А., Оттева Э.Н., Дубинина Т.В., Бадокин В.В., Бочкова А.Г., Бугрова О.В., Годзенко А.А., Дубиков А.И., Иванова О.Н., Коротаева Т.В., Несмеянова О.Б., Никишина И.П., Раскина Т.А., Румянцева О.А., Смирнов А.В., Ситало А.В., Эрдес Ш.Ф., 20172017Гайдукова И.З., Ребров А.П., Лапшина С.А., Оттева Э.Н., Дубинина Т.В., Бадокин В.В., Бочкова А.Г., Бугрова О.В., Годзенко А.А., Дубиков А.И., Иванова О.Н., Коротаева Т.В., Несмеянова О.Б., Никишина И.П., Раскина Т.А., Румянцева О.А., Смирнов А.В., Ситало А.В., Эрдес Ш.Ф.Gaidukova I.Z., Rebrov A.P., Lapshina S.A., Otteva E.N., Dubinina T.V., Badokin V.V., Bochkova A.G., Bugrova O.V., Godzenko A.A., Dubikov A.I., Ivanova O.N., Korotaeva T.V., Nesmeyanova O.B., Nikishina I.P., Raskina T.A., Rumyantseva O.A., Smirnov A.V., Sitalo A.V., Erdes S.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2428

В статье представлены рекомендации по лекарственной терапии аксиальных спондилоартритов, разработанные Экспертной группой по изучению спондилоартритов (ЭкСпА). Рекомендации описывают тактику ведения пациентов в наиболее частых клинических ситуациях, направленную на обеспечение максимальной эффективности и безопасности лечения.

The paper gives recommendations for the drug therapy of axial spondyloarthritides, which have been developed by the Spondyloarthritis Study Group of Experts. The recommendations describe the patient management tactic in the most common clinical situations, which is aimed at maximizing the efficacy and safety of treatment.

спондилоартритыаксиальные спондилоартритыанкилозирующий спондилитболезнь Бехтереванестероидные противовоспалительные препаратыингибиторы фактора некроза опухоли αингибиторы интерлейкина 17безопасность терапииspondyloarthritidesaxial spondyloarthritidesankylosing spondylitisBechterew’s diseasenonsteroidal anti-inflammatory drugstumor necrosis factor-α inhibitorsinterleukin-17 inhibitorssafety of therapyReferencesЭрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60 [Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(6):657-60 (In Russ.)]. doi: 10.14412/1995-4484-2015-657-660Эрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60 [Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(6):657-60 (In Russ.)]. doi: 10.14412/1995-4484-2015-657-660Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777-83. doi: 10.1136/ard.2009.108233Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777-83. doi: 10.1136/ard.2009.108233Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014;73(1):238-42. doi: 10.1136/annrheumdis-2013-203860Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014;73(1):238-42. doi: 10.1136/annrheumdis-2013-203860Gonzalez-Alvaro I, Martinez-Fernandez C, Dorantes-Calderon B, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015 Jul;54(7):1200-9. doi: 10.1093/rheumatology/keu461Gonzalez-Alvaro I, Martinez-Fernandez C, Dorantes-Calderon B, et al. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015 Jul;54(7):1200-9. doi: 10.1093/rheumatology/keu461Ward MM. Update on the American College of Rheumatology /Spondyloarthritis Research and Treatment Network / Spondylitis Association of America axial spondyloarhtritis treatment guidelines project. Clin Rheumatol. 2014;33(6):739-40. doi: 10.1007/s10067-014-2660-9Ward MM. Update on the American College of Rheumatology /Spondyloarthritis Research and Treatment Network / Spondylitis Association of America axial spondyloarhtritis treatment guidelines project. Clin Rheumatol. 2014;33(6):739-40. doi: 10.1007/s10067-014-2660-9Smolen JS, Schö ls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2017 Jul 6. doi: 10.1136/annrheumdis-2017-211734Smolen JS, Schö ls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2017 Jul 6. doi: 10.1136/annrheumdis-2017-211734Van der Heijde D, Sieper J, Maksymowych WP, et al; Assessment of SpondyloArthritis International Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905- 8. doi: 10.1136/ard.2011.151563Van der Heijde D, Sieper J, Maksymowych WP, et al; Assessment of SpondyloArthritis International Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905- 8. doi: 10.1136/ard.2011.151563Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017. doi: 10.1136/annrheumdis-2016- 210770Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017. doi: 10.1136/annrheumdis-2016- 210770Гайдукова ИЗ, Ребров АП, Шувалова АА. Ремиссия при анкилозирующем спондилите и аксиальных спондилоартритах: современное понимание проблемы. Современная ревматология. 2016;10(1):48-51 [Gaydukova IZ, Rebrov AP, Shuvalova AA. Remission in ankylosing spondylitis and axial spondyloarthritis: A modern understanding of the problem. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(1):48-51 (In Russ.)]. doi: 10.14412/1996-7012-2016-1-48-51Гайдукова ИЗ, Ребров АП, Шувалова АА. Ремиссия при анкилозирующем спондилите и аксиальных спондилоартритах: современное понимание проблемы. Современная ревматология. 2016;10(1):48-51 [Gaydukova IZ, Rebrov AP, Shuvalova AA. Remission in ankylosing spondylitis and axial spondyloarthritis: A modern understanding of the problem. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(1):48-51 (In Russ.)]. doi: 10.14412/1996-7012-2016-1-48-51Poddubnyy D, Gensler LS. Spontaneous, drug-induced, and drugfree remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2014;28(5):807-18. doi: 10.1016/j.berh.2014.10.005Poddubnyy D, Gensler LS. Spontaneous, drug-induced, and drugfree remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2014;28(5):807-18. doi: 10.1016/j.berh.2014.10.005Sieper J. How to define remission in ankylosing spondylitis? Ann Rheum Dis. 2012;71 Suppl 2:i93-5. doi: 10.1136/annrheumdis-2011-200798Sieper J. How to define remission in ankylosing spondylitis? Ann Rheum Dis. 2012;71 Suppl 2:i93-5. doi: 10.1136/annrheumdis-2011-200798Braun J, Kiltz U, Sarholz M, et al. Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. Expert Rev Clin Immunol. 2015:1-12. doi: 10.1586/1744666X.2015.1052795Braun J, Kiltz U, Sarholz M, et al. Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. Expert Rev Clin Immunol. 2015:1-12. doi: 10.1586/1744666X.2015.1052795Гайдукова ИЗ, Ребров АП, Оттева ЭН и др. Применение нестероидных противовоспалительных препаратов для лечения аксиальных спондилоартритов, включая анкилозирующий спондилит, мониторинг эффективности и безопасности (проект рекомендаций группы экспертов по диагностике и лечению спондилоартритов). Научно-практическая ревматология. 2016;54(Прил 1):67-74 [Gaidukova IZ, Rebrov AP, Otteva EN, et al. Use of nonsteroidal anti-inflammatory drugs for the treatment of axial spondyloarthritis, including ankylosing spondylitis, monitoring their efficacy and safety (draft guidelines of the Expert Spondyloarthritis Diagnosis and Treatment Group). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(Suppl 1):67-74 (In Russ.)]. doi: 10.14412/1995-4484-2016-1S-67-74Гайдукова ИЗ, Ребров АП, Оттева ЭН и др. Применение нестероидных противовоспалительных препаратов для лечения аксиальных спондилоартритов, включая анкилозирующий спондилит, мониторинг эффективности и безопасности (проект рекомендаций группы экспертов по диагностике и лечению спондилоартритов). Научно-практическая ревматология. 2016;54(Прил 1):67-74 [Gaidukova IZ, Rebrov AP, Otteva EN, et al. Use of nonsteroidal anti-inflammatory drugs for the treatment of axial spondyloarthritis, including ankylosing spondylitis, monitoring their efficacy and safety (draft guidelines of the Expert Spondyloarthritis Diagnosis and Treatment Group). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(Suppl 1):67-74 (In Russ.)]. doi: 10.14412/1995-4484-2016-1S-67-74Лапшина СА, Дубинина ТВ, Бадокин ВВ и др. Ингибиторы фактора некроза опухоли α в лечении аксиальных спондилоартритов (включая анкилозирующий спондилит). Научно-практическая ревматология. 2016;54(Прил 1):75-9 [Lapshina SA, Dubinina TV, Badokin VV, et al. Tumor necrosis factor- α inhibitors in the treatment of axial spondyloarthritis, including ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(Suppl. 1):75-9 (In Russ.)]. doi: 10.14412/1995-4484-2016-1S-75-79Лапшина СА, Дубинина ТВ, Бадокин ВВ и др. Ингибиторы фактора некроза опухоли α в лечении аксиальных спондилоартритов (включая анкилозирующий спондилит). Научно-практическая ревматология. 2016;54(Прил 1):75-9 [Lapshina SA, Dubinina TV, Badokin VV, et al. Tumor necrosis factor- α inhibitors in the treatment of axial spondyloarthritis, including ankylosing spondylitis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(Suppl. 1):75-9 (In Russ.)]. doi: 10.14412/1995-4484-2016-1S-75-79Каратеев АЕ. Комментарий к статье И.З. Гайдуковой и соавт. «Применение нестероидных противовоспалительных препаратов для лечения аксиальных спондилоартритов, включая анкилозирующий спондилит, мониторинг эффективности и безопасности (проект рекомендаций группы экспертов по диагностике и лечению спондилоартритов)». Научно-практическая ревматология. 2016;54(3):367-9 [Karateev AE. Commentary on the paper «Use of nonsteroidal anti-inflammatory drugs for the treatment of axial spondyloarthrititides, including ankylosing spondylitis, monitoring their efficacy and safety (draft guidelines of the Expert Spondyloarthritis Diagnosis and Treatment Group)» by I.Z. Gaidukova et al. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):367-9 (In Russ.)]. doi: 10.14412/1995-4484-2016-367-369Каратеев АЕ. Комментарий к статье И.З. Гайдуковой и соавт. «Применение нестероидных противовоспалительных препаратов для лечения аксиальных спондилоартритов, включая анкилозирующий спондилит, мониторинг эффективности и безопасности (проект рекомендаций группы экспертов по диагностике и лечению спондилоартритов)». Научно-практическая ревматология. 2016;54(3):367-9 [Karateev AE. Commentary on the paper «Use of nonsteroidal anti-inflammatory drugs for the treatment of axial spondyloarthrititides, including ankylosing spondylitis, monitoring their efficacy and safety (draft guidelines of the Expert Spondyloarthritis Diagnosis and Treatment Group)» by I.Z. Gaidukova et al. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):367-9 (In Russ.)]. doi: 10.14412/1995-4484-2016-367-369Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of АS. Ann Rheum Dis. 2011;70:896-904. doi: 10.1136/ard.2011.151027896Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of АS. Ann Rheum Dis. 2011;70:896-904. doi: 10.1136/ard.2011.151027896Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011 Aug;70(8):1369-74. doi: 10.1136/ard.2010.145995Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011 Aug;70(8):1369-74. doi: 10.1136/ard.2010.145995Poddubnyy D, Sieper J. Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful? Curr Opin Rheumatol. 2012 Jul;24(4):363-9. doi: 10.1097/BOR.0b013e328352b7bdPoddubnyy D, Sieper J. Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful? Curr Opin Rheumatol. 2012 Jul;24(4):363-9. doi: 10.1097/BOR.0b013e328352b7bdInman WH. Non-steroidal anti-inflammatory drugs: assessment of risks. Eur J Rheumatol Inflamm. 1987;8(1):71-85.Inman WH. Non-steroidal anti-inflammatory drugs: assessment of risks. Eur J Rheumatol Inflamm. 1987;8(1):71-85.Bennett N, McGonagle D, O’Connor P, et al. Severity of baseline magnetic resonance imaging–evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008;58(11):3413-8. doi: 10.1002/art.24024Bennett N, McGonagle D, O’Connor P, et al. Severity of baseline magnetic resonance imaging–evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008;58(11):3413-8. doi: 10.1002/art.24024Burd TA, Hughes MS, Anglen JO. Heterotopic ossifi cation prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br. 2003;85:700- 5. doi: 10.1302/0301-620X.85B5.13970Burd TA, Hughes MS, Anglen JO. Heterotopic ossifi cation prophylaxis with indomethacin increases the risk of long-bone nonunion. J Bone Joint Surg Br. 2003;85:700- 5. doi: 10.1302/0301-620X.85B5.13970Bhattacharyya T, Levin R, Vrahas MS, et al. Nonsteroidal antiinfl ammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum. 2005;53:364-7. doi: 10.1002/art.21170Bhattacharyya T, Levin R, Vrahas MS, et al. Nonsteroidal antiinfl ammatory drugs and nonunion of humeral shaft fractures. Arthritis Rheum. 2005;53:364-7. doi: 10.1002/art.21170Persson PE, Nilsson OS, Berggren AM. Do non-steroidal anti-infl ammatory drugs cause endoprosthetic loosening? A 10-year follow- up of a randomized trial on ibuprofen for prevention of heterotopic ossification after hip arthroplasty. Acta Orthop. 2005;76:735-40. doi: 10.1080/17453670510045309Persson PE, Nilsson OS, Berggren AM. Do non-steroidal anti-infl ammatory drugs cause endoprosthetic loosening? A 10-year follow- up of a randomized trial on ibuprofen for prevention of heterotopic ossification after hip arthroplasty. Acta Orthop. 2005;76:735-40. doi: 10.1080/17453670510045309Gensler L, Reveille J, Lee M, et al. High dose nonsteroidal Anti-Inflammatory drugs (NSAIDs) and tumor necrosis factor Inhibitor Use results in less radiographic progression in Ankylosing Spondylitis – a Longitudinal Analysis [abstract]. Arthritis Rheum. 2016;68 Suppl 10:2481-2.Gensler L, Reveille J, Lee M, et al. High dose nonsteroidal Anti-Inflammatory drugs (NSAIDs) and tumor necrosis factor Inhibitor Use results in less radiographic progression in Ankylosing Spondylitis – a Longitudinal Analysis [abstract]. Arthritis Rheum. 2016;68 Suppl 10:2481-2.Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open. 2015;1 Suppl 1:e000053. doi: 10.1136/rmdopen-2015-000053Baraliakos X, Braun J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? RMD Open. 2015;1 Suppl 1:e000053. doi: 10.1136/rmdopen-2015-000053Эрдес ШФ, Дубинина ТВ, Румянцева ОА и др. Эволюция аксиального спондилоартрита за 12 месяцев наблюдения когорты КоРСаР. Научно-практическая ревматология. 2016;54(Прил 1):55-9 [Erdes ShF, Dubinina TV, Rumyantseva OA, et al. The evolution of axial spondyloarthritis during 12-month follow-up study of a CoRSaR cohort. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(Suppl. 1):55-9 (In Russ.)]. doi: 10.14412/1995-4484-2016-1S-55-59Эрдес ШФ, Дубинина ТВ, Румянцева ОА и др. Эволюция аксиального спондилоартрита за 12 месяцев наблюдения когорты КоРСаР. Научно-практическая ревматология. 2016;54(Прил 1):55-9 [Erdes ShF, Dubinina TV, Rumyantseva OA, et al. The evolution of axial spondyloarthritis during 12-month follow-up study of a CoRSaR cohort. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(Suppl. 1):55-9 (In Russ.)]. doi: 10.14412/1995-4484-2016-1S-55-59Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;(1):4-23 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti- inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;(1):4-23 (In Russ.)]. doi: 10.14412/1996-7012-2015-1-4-23Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;(1):4-23 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti- inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;(1):4-23 (In Russ.)]. doi: 10.14412/1996-7012-2015-1-4-23Malfertheiner P, Megraud F, O’Morain CA, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.Malfertheiner P, Megraud F, O’Morain CA, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.Chan FK, Graham DY. Review article: prevention of nonsteroidal anti-inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004;19(10):1051-61. doi: 10.1136/ard.2010.128660Chan FK, Graham DY. Review article: prevention of nonsteroidal anti-inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004;19(10):1051-61. doi: 10.1136/ard.2010.128660Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non- steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther. 2004;19(2):197-208. doi: 10.1111/j.1365-2125.2007.03038Dubois RW, Melmed GY, Henning JM, Laine L. Guidelines for the appropriate use of non- steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther. 2004;19(2):197-208. doi: 10.1111/j.1365-2125.2007.03038Kono Y, Okada H, Takenaka R, et al. Does Helicobacter pylori exacerbate gastric mucosal injury in users of nonsteroidal antiinflammatory drugs? A multicenter, retrospective, case- control study. Gut Liver. 2016 Jan;10(1):69-75. doi: 10.5009/gnl14372Kono Y, Okada H, Takenaka R, et al. Does Helicobacter pylori exacerbate gastric mucosal injury in users of nonsteroidal antiinflammatory drugs? A multicenter, retrospective, case- control study. Gut Liver. 2016 Jan;10(1):69-75. doi: 10.5009/gnl14372Sostres C, Jerusalen Gargallo C, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights. World J Gastroenterol. 2014;20(28):9439-50. doi: 10.3748/wjg.v20.i28.9439Sostres C, Jerusalen Gargallo C, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights. World J Gastroenterol. 2014;20(28):9439-50. doi: 10.3748/wjg.v20.i28.9439Greenland P, Alpert JS, Beller GA, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Circulation. 2010;2010(122):e584-e636. doi: 10.1016/j.jacc.2013.11.005Greenland P, Alpert JS, Beller GA, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Circulation. 2010;2010(122):e584-e636. doi: 10.1016/j.jacc.2013.11.005Orford JL, Sesso HD, Stedman MA, et al. Comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. Am Heart J. 2002 Jul;144(1):95-100. doi: 10.1067/mhj.2002.123317Orford JL, Sesso HD, Stedman MA, et al. Comparison of the Framingham and European Society of Cardiology coronary heart disease risk prediction models in the normative aging study. Am Heart J. 2002 Jul;144(1):95-100. doi: 10.1067/mhj.2002.123317Tsai WC, Ou TT, Yen JH, et al. Long-term frequent use of nonsteroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One. 2015;10(5):e0126347. doi: 10.1371/journal.pone.0126347. eCollection 2015.Tsai WC, Ou TT, Yen JH, et al. Long-term frequent use of nonsteroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study. PLoS One. 2015;10(5):e0126347. doi: 10.1371/journal.pone.0126347. eCollection 2015.Ikdahl E, Rollefstad S, Olsen IC, et al. EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic. Biomed Res Int. 2015;2015:515280. doi: 10.1155/2015/515280Ikdahl E, Rollefstad S, Olsen IC, et al. EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic. Biomed Res Int. 2015;2015:515280. doi: 10.1155/2015/515280Heslinga SC, van den Oever IA, van Sijl AM, et al. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord. 2015;16:80. doi: 10.1186/s12891-015-0532-3Heslinga SC, van den Oever IA, van Sijl AM, et al. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord. 2015;16:80. doi: 10.1186/s12891-015-0532-3Rafaniello C, Ferrajolo C, Sullo MG, et al. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. Pharmacol Res. 2015 Dec 29;104:108-14. doi: 10.1016/j.phrs.2015.12.026Rafaniello C, Ferrajolo C, Sullo MG, et al. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. Pharmacol Res. 2015 Dec 29;104:108-14. doi: 10.1016/j.phrs.2015.12.026Rosen E, Tsesis I, Vered M. [U.S. Food and Drug Administration (FDA) strengthens warning that non-aspirin non steroidal antiinflammatory drugs (NSAIDs) can cause myocardial infarctions or strokes: the dentist's perspective]. Refuat Hapeh Vehashinayim. 1993;32(4):6-10.Rosen E, Tsesis I, Vered M. [U.S. Food and Drug Administration (FDA) strengthens warning that non-aspirin non steroidal antiinflammatory drugs (NSAIDs) can cause myocardial infarctions or strokes: the dentist's perspective]. Refuat Hapeh Vehashinayim. 1993;32(4):6-10.Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. 2015 Sep;66(3):524-33. doi: 10.1161/hypertensionaha.114.05105Hsu CC, Wang H, Hsu YH, et al. Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Subjects With Hypertension: Nationwide Longitudinal Cohort Study. Hypertension. 2015 Sep;66(3):524-33. doi: 10.1161/hypertensionaha.114.05105Ingrasciotta Y, Sultana J, Giorgianni F, et al. Association of individual non-steroidal anti- inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS One. 2015 Apr 16;10(4):e0122899. doi: 10.1371/journal.pone.0122899.eCollection 2015.Ingrasciotta Y, Sultana J, Giorgianni F, et al. Association of individual non-steroidal anti- inflammatory drugs and chronic kidney disease: a population-based case control study. PLoS One. 2015 Apr 16;10(4):e0122899. doi: 10.1371/journal.pone.0122899.eCollection 2015.Cao YL, Tian ZG, Wang F, et al. Characteristics and clinical outcome of nonsteroidal anti- inflammatory drug-induced acute hepato-nephrotoxicity among Chinese patients. World J Gastroenterol. 2014;20(38):13956-65. doi: 10.3748/wjg.v20.i38.13956Cao YL, Tian ZG, Wang F, et al. Characteristics and clinical outcome of nonsteroidal anti- inflammatory drug-induced acute hepato-nephrotoxicity among Chinese patients. World J Gastroenterol. 2014;20(38):13956-65. doi: 10.3748/wjg.v20.i38.13956Nderitu P, Doos L, Jones PW, et al. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013;30(3):247-55. doi: 10.1177/2050640613502900Nderitu P, Doos L, Jones PW, et al. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Fam Pract. 2013;30(3):247-55. doi: 10.1177/2050640613502900Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014;7:457-68. doi: 10.2147/IJNRD.S39747Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014;7:457-68. doi: 10.2147/IJNRD.S39747Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012;71 Suppl 2;i2-45. doi: 10.1136/ard.2010.144998Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012;71 Suppl 2;i2-45. doi: 10.1136/ard.2010.144998Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011 Jan; 70(1):25-31. doi: 10.1136/ard.2010.133645Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011 Jan; 70(1):25-31. doi: 10.1136/ard.2010.133645Lukas C, Landewe R, Sieper J, et al. Development of an ASASendorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Assessment of SpondyloArthritis international Society. Ann Rheum Dis. 2009;68(1):18-24. doi: 10.1136/ard.2008.094870Lukas C, Landewe R, Sieper J, et al. Development of an ASASendorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Assessment of SpondyloArthritis international Society. Ann Rheum Dis. 2009;68(1):18-24. doi: 10.1136/ard.2008.094870Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015 Apr 18;4:CD005468. doi: 10.1002/14651858.CD005468.pub2Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015 Apr 18;4:CD005468. doi: 10.1002/14651858.CD005468.pub2Wu D, Guo YY, Xu NN, et al. Efficacy of anti-tumor necrosis factor therapy for extra- articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord. 2015 Feb 10;16:19. doi: 10.1186/s12891-015-0489-2Wu D, Guo YY, Xu NN, et al. Efficacy of anti-tumor necrosis factor therapy for extra- articular manifestations in patients with ankylosing spondylitis: a meta-analysis. BMC Musculoskelet Disord. 2015 Feb 10;16:19. doi: 10.1186/s12891-015-0489-2Mackay K, Brophy S, Mack C, et al. The development and validation of a radiographic grading system for the hip in Ankylosing Spondylitis: the Bath Ankylosing Spondylitis Radiology Hip Index. J Rheumatol. 2000;27:2866-72.Mackay K, Brophy S, Mack C, et al. The development and validation of a radiographic grading system for the hip in Ankylosing Spondylitis: the Bath Ankylosing Spondylitis Radiology Hip Index. J Rheumatol. 2000;27:2866-72.Резюме Совета экспертов «Вопросы “выживаемости” генно-инженерных биологических препаратов и возможности переключения на секукинумаб при анкилозирующем спондилите в реальной клинической практике» Москва, 10 февраля 2017 г. Научно-практическая ревматология. 2017;55(2):230-1 [The Expert Board’s Abstract on Questions of the survival of biological agents and the possibility of switching to secukinumab in ankylosing spondilitis in real clinical practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):230-1 (In Russ.)]. doi: 10.14412/1995-4484-2017-230-231Резюме Совета экспертов «Вопросы “выживаемости” генно-инженерных биологических препаратов и возможности переключения на секукинумаб при анкилозирующем спондилите в реальной клинической практике» Москва, 10 февраля 2017 г. Научно-практическая ревматология. 2017;55(2):230-1 [The Expert Board’s Abstract on Questions of the survival of biological agents and the possibility of switching to secukinumab in ankylosing spondilitis in real clinical practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(2):230-1 (In Russ.)]. doi: 10.14412/1995-4484-2017-230-231Arends S, Lebbink HR, Spoorenberg A, et al. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2010;28(5):661-8. doi: 10.1186/ar3369Arends S, Lebbink HR, Spoorenberg A, et al. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2010;28(5):661-8. doi: 10.1186/ar3369Plasencia C, Pascual-Salcedo D, Nuno L, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012;71(12):1955-60. doi: 10.1136/annrheumdis-2011-200828Plasencia C, Pascual-Salcedo D, Nuno L, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012;71(12):1955-60. doi: 10.1136/annrheumdis-2011-200828Murdaca G, Spano F, Contatore M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43-52. doi: 10.1517/14740338.2016.1112375Murdaca G, Spano F, Contatore M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43-52. doi: 10.1517/14740338.2016.1112375Гайдукова ИЗ, Ребров АП, Апаркина АВ, Хондкарян ЭВ. Концентрация интерлейкина-17а остается стабильно высокой у больных анкилозирующим спондилитом, получающих ингибиторы фактора некроза опухоли α в течение года. Терапевтический архив. 2017;89(4):80-5 [Gaydukova IZ, Rebrov AP, Aparkina AV, Khondkaryan EV. Stable high interleukin-17A concentration in patients with ankylosing spondylitis treated with tumor necrosis factor-α inhibitors during a year. Therapevticheskyy Archiv. 2017;89(4):80-5 (In Russ)]. doi: 10.17116/terarkh201789480-85Гайдукова ИЗ, Ребров АП, Апаркина АВ, Хондкарян ЭВ. Концентрация интерлейкина-17а остается стабильно высокой у больных анкилозирующим спондилитом, получающих ингибиторы фактора некроза опухоли α в течение года. Терапевтический архив. 2017;89(4):80-5 [Gaydukova IZ, Rebrov AP, Aparkina AV, Khondkaryan EV. Stable high interleukin-17A concentration in patients with ankylosing spondylitis treated with tumor necrosis factor-α inhibitors during a year. Therapevticheskyy Archiv. 2017;89(4):80-5 (In Russ)]. doi: 10.17116/terarkh201789480-85Cantini F, Niccoli L, Cassara E, et al. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow- upstudy. Biologics. 2013;7:1-6. doi: 10.2147/BTT.S31474Cantini F, Niccoli L, Cassara E, et al. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow- upstudy. Biologics. 2013;7:1-6. doi: 10.2147/BTT.S31474Arends S, van der Veer E, Kamps FB, et al. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol. 2015;33(2):174-80.Arends S, van der Veer E, Kamps FB, et al. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol. 2015;33(2):174-80.Olivieri I, D’Angelo S, Padula A, et al. Can we reduce the dosage of biologics in spondyloarthritis? Autoimmun Rev. 2013 May;12(7):691-3. doi: 10.1016/j.autrev.2012.08.013Olivieri I, D’Angelo S, Padula A, et al. Can we reduce the dosage of biologics in spondyloarthritis? Autoimmun Rev. 2013 May;12(7):691-3. doi: 10.1016/j.autrev.2012.08.013Song IH, Haibel H, Poddubnyy D, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol. 2013 Jul-Aug;31 4 Suppl 78:S37-42.Song IH, Haibel H, Poddubnyy D, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol. 2013 Jul-Aug;31 4 Suppl 78:S37-42.Spadaro A, Punzi L, Marchesoni A, et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford). 2010;49(6);1107-11. doi: 10.1016/S0140-6736(17)30068-5Spadaro A, Punzi L, Marchesoni A, et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford). 2010;49(6);1107-11. doi: 10.1016/S0140-6736(17)30068-5Braun J, Sieper J. Remission and possible discontinuation of biological therapy in axial spondyloarthritis. Clin Exp Rheumatol. 2013;31 Suppl 78:S33-6.Braun J, Sieper J. Remission and possible discontinuation of biological therapy in axial spondyloarthritis. Clin Exp Rheumatol. 2013;31 Suppl 78:S33-6.Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2017 May;18:1-23. doi: 10.1080/09546634.2017.1329511Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2017 May;18:1-23. doi: 10.1080/09546634.2017.1329511Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066Accortt NA, Bonafede MM, Collier DH, et al. Risk of subsequent infection among patients receiving tumor necrosis factor inhibitors and other disease-modifying antirheumatic drugs. Arthritis Rheum. 2016;68(1):67-76. doi: 10.1002/art.39416Accortt NA, Bonafede MM, Collier DH, et al. Risk of subsequent infection among patients receiving tumor necrosis factor inhibitors and other disease-modifying antirheumatic drugs. Arthritis Rheum. 2016;68(1):67-76. doi: 10.1002/art.39416Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15 Supp1:11-34. doi: 10.1080/14740338.2016.1240783Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15 Supp1:11-34. doi: 10.1080/14740338.2016.1240783Ooka K, Lim JK. Treatment of hepatitis C in patients undergoing immunosuppressive drug therapy. J Clin Transl Hepatol. 2016 Sep 28;4(3):206-27. doi: 10.14218/JCTH.2016.00017Ooka K, Lim JK. Treatment of hepatitis C in patients undergoing immunosuppressive drug therapy. J Clin Transl Hepatol. 2016 Sep 28;4(3):206-27. doi: 10.14218/JCTH.2016.00017Valaydon Z, Pellegrini M, Thompson A, et al. The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. Clin Transl Immunol. 2016;5(12):e115. doi: 10.1038/cti.2016.68Valaydon Z, Pellegrini M, Thompson A, et al. The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. Clin Transl Immunol. 2016;5(12):e115. doi: 10.1038/cti.2016.68Белов БС. Терапия генно-инженерными биологическими препаратами и инфекции у больных ревматоидным артритом: актуальность и перспективы. Научно- практическая ревматология. 2014;52(3):322-30 [Belov BS. Biological therapy and infections in patients with rheumatoid arthritis: relevance and prospects. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(3):322-30 (In Russ.)]. doi: 10.14412/1995-4484-2014-322-330Белов БС. Терапия генно-инженерными биологическими препаратами и инфекции у больных ревматоидным артритом: актуальность и перспективы. Научно- практическая ревматология. 2014;52(3):322-30 [Belov BS. Biological therapy and infections in patients with rheumatoid arthritis: relevance and prospects. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(3):322-30 (In Russ.)]. doi: 10.14412/1995-4484-2014-322-330Wangsiricharoen S, Ligon C, Gedmintas L, et al. The rates of serious infections in HIV- infected patients who received tumor necrosis factor (TNF)-α inhibitor therapy for concomitant autoimmune diseases. Arthritis Care Res (Hoboken). 2017;69(3):449-52. doi: 10.1002/acr.22955Wangsiricharoen S, Ligon C, Gedmintas L, et al. The rates of serious infections in HIV- infected patients who received tumor necrosis factor (TNF)-α inhibitor therapy for concomitant autoimmune diseases. Arthritis Care Res (Hoboken). 2017;69(3):449-52. doi: 10.1002/acr.22955Aboulafia DM, Bundow D, Wilske K, Ocas UI. Etanercept for the Treatment of Human Immunodeficiency Virus-Associated Psoriatic Arthritis. Mayo Clin Proc. 2000;75:1093-8. doi: 10.4065/75.10.1093Aboulafia DM, Bundow D, Wilske K, Ocas UI. Etanercept for the Treatment of Human Immunodeficiency Virus-Associated Psoriatic Arthritis. Mayo Clin Proc. 2000;75:1093-8. doi: 10.4065/75.10.1093Mikhail M, Weinberg JM, Smith BL. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol. 2008 Apr;144(4):453-6. doi: 10.1001/archderm.144.4.453Mikhail M, Weinberg JM, Smith BL. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol. 2008 Apr;144(4):453-6. doi: 10.1001/archderm.144.4.453Cepeda EJ, Williams FM, Ishimori MLet al. The use of antitumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis. 2008;67:710-2. doi: 10.1136/ard.2007.081513Cepeda EJ, Williams FM, Ishimori MLet al. The use of antitumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis. 2008;67:710-2. doi: 10.1136/ard.2007.081513Gallitano SM, McDermott L, Brar K, Lowenstein E. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016 May;74(5):974-80. doi: 10.1016/j.jaad.2015.11.043. Epub 2016 Jan 14.Gallitano SM, McDermott L, Brar K, Lowenstein E. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol. 2016 May;74(5):974-80. doi: 10.1016/j.jaad.2015.11.043. Epub 2016 Jan 14.Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS. 2004;18:257-64. doi: 10.1016/j.jaad.2015.11.043Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS. 2004;18:257-64. doi: 10.1016/j.jaad.2015.11.043Solomon DH, Mercer E, Kavanaugh A. Observational Studies on the Risk of Cancer Associated with TNF-Inhibitors in RA: A Review of their Methodologies and Results. Arthritis Rheum. 2012;64(1):21-32. doi: 10.1002/art.30653Solomon DH, Mercer E, Kavanaugh A. Observational Studies on the Risk of Cancer Associated with TNF-Inhibitors in RA: A Review of their Methodologies and Results. Arthritis Rheum. 2012;64(1):21-32. doi: 10.1002/art.30653

The authors declare that there are no conflicts of interest present.